Crisaborole(AN-2728)

Biological Activity

AN-2728 is a topically administered, boron-containing, anti-inflammatory compound that inhibits PDE4 activity and thereby suppresses the release of TNFalpha, IL-12, IL-23 and other cytokines. AN-2728 appears to have good therapeutic potential, although further and larger trials are required to assess the long-term safety and characterize the broad utility of this drug. AN-2728 shows potent activity both in vitro and in vivo. AN-2728 is now in clinical development for the topical treatment of psoriasis and being pursued for the topical treatment of atopic dermatitis.For the detailed information of AN-2728, the solubility of AN-2728 in water, the solubility of AN-2728 in DMSO, the solubility of AN-2728 in PBS buffer, the animal experiment (test) of AN-2728, the cell expriment (test) of AN-2728, the in vivo, in vitro and clinical trial test of AN-2728, the EC50, IC50,and affinity,of AN-2728, Please contact DC Chemicals.

Published experimental findings depend on the model and assay conditions. They do not guarantee equivalent performance in every application. For laboratory research use only.